L 703801
Latest Information Update: 14 Mar 2000
At a glance
- Originator Merck & Co
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 14 Mar 2000 No-Development-Reported for Thrombosis in USA (Unknown route)
- 09 Apr 1997 New profile
- 09 Apr 1997 Preclinical development for Thrombosis in USA (Unknown route)